Claritev (NYSE:CTEV) Receives Consensus Rating of “Moderate Buy” from Brokerages

Posted by Stanley Muller on May 19th, 2026

Shares of Claritev (NYSE:CTEV – Get Free Report) have been given an average rating of “Moderate Buy” by the six analysts that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $27.25.

A number of analysts have recently issued reports on the stock. Citigroup reaffirmed a “buy” rating on shares of Claritev in a report on Wednesday, May 13th. Wall Street Zen downgraded shares of Claritev from a “hold” rating to a “sell” rating in a research note on Saturday, April 25th. Wells Fargo & Company lowered their price target on shares of Claritev from $30.00 to $22.00 and set an “equal weight” rating for the company in a research note on Thursday, March 19th. Barclays initiated coverage on shares of Claritev in a research note on Friday, April 24th. They issued an “overweight” rating and a $28.00 price target for the company. Finally, UBS Group reissued a “buy” rating on shares of Claritev in a research note on Tuesday, February 24th.

Read Our Latest Stock Analysis on Claritev

Insider Buying and Selling at Claritev

In other Claritev news, CEO Travis Dalton purchased 15,380 shares of the stock in a transaction on Friday, February 27th. The stock was acquired at an average cost of $13.00 per share, with a total value of $199,940.00. Following the completion of the purchase, the chief executive officer directly owned 24,952 shares of the company’s stock, valued at approximately $324,376. This trade represents a 160.68% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Michael Kim purchased 15,000 shares of the stock in a transaction on Thursday, March 12th. The stock was acquired at an average cost of $16.50 per share, with a total value of $247,500.00. Following the completion of the purchase, the executive vice president directly owned 182,878 shares of the company’s stock, valued at $3,017,487. The trade was a 8.94% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders acquired 61,680 shares of company stock valued at $899,437 over the last three months. 7.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Claritev

Several hedge funds and other institutional investors have recently modified their holdings of CTEV. H&F Corporate Investors VIII Ltd. purchased a new stake in shares of Claritev during the third quarter worth about $285,988,000. AustralianSuper Pty Ltd bought a new position in Claritev during the 3rd quarter valued at approximately $169,605,000. Arini Captial Management Ltd bought a new position in Claritev during the 4th quarter valued at approximately $64,291,000. Public Investment Fund purchased a new stake in Claritev in the 3rd quarter worth approximately $68,009,000. Finally, Beach Point Capital Management LP grew its position in shares of Claritev by 77.4% in the 4th quarter. Beach Point Capital Management LP now owns 755,002 shares of the company’s stock worth $32,276,000 after buying an additional 329,424 shares during the last quarter. 87.15% of the stock is owned by institutional investors.

Claritev Stock Performance

NYSE CTEV opened at $16.65 on Tuesday. Claritev has a 52-week low of $11.50 and a 52-week high of $74.07. The company has a market capitalization of $283.88 million, a P/E ratio of -0.96 and a beta of 0.76. The company has a fifty day moving average of $19.46 and a 200-day moving average of $30.59.

About Claritev

(Get Free Report)

Claritev is a healthcare technology, data and insights company focused on improving affordability, transparency and quality. Led by deeply experienced associates, data scientists, and innovators, Claritev provides tech-enabled solutions and services fueled by multiple data sources from over 40 years of claims repricing. Claritev utilizes world-class technology and AI solutions to power a robust enterprise platform that delivers meaningful insights to drive affordability in healthcare, brings price transparency and optimizes networks and benefits design.